Community pharmacy: a crucial enabler in creating the effectiveness study environment in the Salford Lung Studies. (26th June 2020)

• Record Type: Journal Article
• Authors: Leather, David A; Howard, Steve; Haydock, Gerry; Stephens, Linda
• Is Part Of: International journal of pharmacy practice. Volume 28:Number 5(2020)
• Page Start: 529
• Page End: 533
• Publication Date: 2020-06-26
• Subjects: Clinical Practic -- Community Pharmacy -- Effectiveness Trial -- Primary Care -- Salford Lung Studies; Pharmacy -- Practice -- Periodicals; 615.1
• DOI: 10.1111/ijpp.12647
• Languages: English
• ISSNs: 0961-7671

Abstract

Abstract: Objective: Creating an environment that supports conditions of routine clinical practice and enables an effectiveness trial design with a pre-licensed medicine is extremely challenging. Here, we summarise our experiences and achievements with engaging and mobilising community pharmacies in and around Salford, United Kingdom, in the Phase III effectiveness Salford Lung Studies (SLS). Methods: This article provides the authors' personal experiences and viewpoints on community pharmacy involvement in the SLS. Key findings: More than 130 community pharmacies were enabled, and >2500 pharmacy staff trained, for involvement in the SLS. Key to community pharmacy participation in the SLS was the formation of the SLS Pharmacy Steering Group (PSG), contributing to study oversight, and the development of a pharmacy standard operating procedure document, the major principle of which was to ensure minimum disruption to the normal medicine dispensing process while ensuring compliance with regulations, guidelines, good clinical practice and requirements for pharmacovigilance. The high level of commitment and collaboration of community pharmacy in the SLS demonstrated a willingness to work together and take on additional and novel roles beyond their everyday commercial functions for the benefit of patients, despite normally competing for prescription business. Conclusions: The involvement and integration of community pharmacy as a key partner in the SLS was pivotal in securing the delivery of these world-first clinical effectiveness studies. To our knowledge, this has not been previously achieved in a study of a pre-licensed maintenance therapy for a common disease in primary care.